Company Directory

Drug discovery platform targeting biomolecular condensates

Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify small-molecule candidates against targets previously considered undruggable. Lead programmes include a collaboration with Voyager Therapeutics targeting TDP-43 in ALS and frontotemporal dementia, and an internal oncology programme targeting MYC-driven cancers.

Human iPSC platform for neurodegenerative disease drug discovery

Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial health, and an external collaboration programme. Talisman's iPSC-derived neural cell models are designed to improve the relevance and predictivity of early-stage compound screening.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

Clinical trial delivery for Alzheimer's and neurodegenerative disease

Scottish Brain Sciences is a contract research organisation building and operating clinical trial infrastructure for Alzheimer's disease and other neurodegenerative conditions. Working with pharmaceutical sponsors, it delivers trial screening, patient recruitment, and study conduct at dedicated clinical sites in Edinburgh and Aberdeen. Its capabilities span blood biomarker testing, neuroimaging, and cognitive assessment, enabling early detection and participant identification for disease-modifying therapy trials.

Real-world mental health and dementia data platform for drug development

Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural language processing. Commercial applications include health economics and outcomes research, clinical trial patient recruitment, pharmacovigilance, and drug discovery target identification.

Multimodal small molecule therapeutics for neurodegenerative disease

Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously, addressing the limitations of existing single-pathway strategies. Elixa operates as a virtual biotech, outsourcing all R&D activity, with a strategy of advancing lead candidates to first-in-human readiness before seeking development and commercialisation partners.

C. elegans whole-organism platform for preclinical drug and compound screening

Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics across large worm populations, supporting compound library screening, pathway analysis, microbiome assessment, and toxicology studies. The platform accelerates early compound triage for pharmaceutical, biotechnology, and nutrition clients, reducing reliance on mammalian models.

Single-workflow sequencing technology capturing genetic and epigenetic data

biomodal is a Cambridge-based life sciences technology company developing multiomics sequencing solutions that simultaneously capture genetic and epigenetic information from a single DNA sample. Its multiomics platform detects the canonical four DNA bases alongside 5-methylcytosine and 5-hydroxymethylcytosine modifications at single-base resolution, without requiring additional hardware or bisulfite treatment. The technology is compatible with existing sequencing infrastructure and targets applications in oncology, neurodegenerative disease research, and liquid biopsy diagnostics.

AI-driven neural data platform for bioelectronic medicine

BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation therapies and neural digital therapeutics. BIOS serves pharmaceutical and medical device partners, academic research institutions, and NHS clinical programmes targeting cardiovascular, neurological, and autoimmune conditions.

Specialist CRO for rare disease drug development and commercialisation

TMC Pharma Services is a contract research organisation specialising in drug development support for rare and orphan diseases. The company serves small and mid-sized biotech and biopharma clients across the full development lifecycle, providing regulatory affairs, clinical development, pharmacovigilance, medical services, quality management, and drug commercialisation services including marketing authorisation holder functions. Therapeutic areas of focus include oncology, rare neurological disorders, respiratory disease, and haematology.

Convection enhanced delivery consulting and devices for CNS therapeutics

Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and biotechnology companies, it designs and optimises delivery strategies for gene therapies and other treatments directed at specific brain regions, bypassing the blood-brain barrier. The company develops proprietary implantable neurosurgical delivery devices and provides pre-clinical and clinical trial support for CNS drug delivery programmes in neurodegenerative, neuro-oncological, and rare neurological conditions.

Contract proteomics CRO and inventor of TMT isobaric mass tags

Proteome Sciences is a contract proteomics organisation and reagent manufacturer specialising in mass spectrometry-based protein biomarker discovery, validation, and targeted assay development. Its proprietary workflows serve pharmaceutical and biotechnology clients across drug discovery and clinical research. The company invented Tandem Mass Tag isobaric labelling reagents, now manufactured at its Frankfurt laboratory and distributed globally by Thermo Scientific under licence. Disease focus includes neurodegeneration, oncology, and stroke.